Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Orchard
London, England, United Kingdom
- Ownership
- Private
- Employees
- ~166
- Development stage
- Other
01
Overview
Orchard has two commercial-stage gene therapies approved in Europe (Libmeldy for MLD, Strimvelis for ADA-SCID), and a broad clinical pipeline targeting rare genetic, neurodegenerative, and immunological disorders. OTL-200 (Libmeldy) demonstrates transformative efficacy in early-onset MLD, halting disease progression in pivotal trials[2][1][5].
- Therapeutic areas
- ImmunologyGastroenterologyNeurologyRare DiseasesHematology
- Modalities
- Gene therapyCell therapyBiologic
- Industry
- Biotech
02
Partnerships
GlaxoSmithKline (historic asset acquisition)San Raffaele Telethon Institute for Gene TherapyGénéthonThe University of Manchester
Beyond the preview
Go deeper on Orchard.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orchard.